Many people who underwent BRCA genetic testing more than 13 years ago may carry an undetected mutation linked to higher cancer risk. Advances in testing technology since then have revealed limitations in earlier methods. The finding points to a need for updated evaluation in certain cases, according to medical experts. ([1])
Why older tests fell short
BRCA1 and BRCA2 tests analyze genes that help repair DNA damage. Early versions of these tests could not detect every variant now known to increase cancer susceptibility. Laboratory methods have improved substantially, allowing labs to identify additional mutations that were invisible at the time.
These gaps mean some individuals received negative or inconclusive results that no longer reflect current knowledge. The difference stems from expanded variant databases and more sensitive sequencing techniques developed over the past decade.
Who should consider retesting
Anyone tested before roughly 2013 falls into the group that may benefit from a fresh look. Family history of breast, ovarian, or related cancers adds further reason to review past results with a specialist. Not every older test requires immediate action, yet the possibility of a missed variant warrants discussion.
Physicians can review the original report and determine whether updated panels would provide clearer information. Retesting decisions remain individual and depend on personal medical context.
Expert view on the scale of the issue
Dr. Sofia Merajver, a breast cancer researcher, noted the potential reach of the problem. “There are probably thousands of individuals out there who need to be retested,” she said.
Her comment underscores that the issue extends beyond isolated cases. It reflects broader changes in genetic testing standards rather than errors in any single lab.
Next steps for patients
Start by contacting the doctor or genetic counselor who ordered the original test. They can help locate the report and assess whether retesting fits current guidelines. Many clinics now offer expanded panels that include variants missed in earlier rounds.
Insurance coverage and out-of-pocket costs vary, so those factors should be clarified early. A measured conversation with a healthcare provider remains the most reliable path forward.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.